- Molecular NameTroglitazone
- SynonymNA
- Weight441.548
- Drugbank_IDN/A
- ACS_NO97322-87-7
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)4.42
- pkaN/A
- LogD (pH=7, predicted)3.71
- Solubility (experiment)0.000133 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-4.98
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors2
- No.of HBond Acceptors6
- No.of Rotatable Bonds5
- TPSA110.16
- StatusN/A
- AdministrationN/A
- PharmacologyAn anti-diabetic and antiinflammatory drug, and a member of the drug class of the thiazolidinediones.
- Absorption_valueN/A
- Absorption (description)Absorbed rapidly. Food increases the extent of absorption by 30% to 85%.
- Caco_2N/A
- Bioavailability45.0
- Protein binding99.0
- Volume of distribution (VD)Steady state 2.5 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmA sulfate conjugate metabolite (Metabolite 1) and a quinone metabolite (Metabolite 3) have been detected in the plasma of healthy males. A glucuronide conjugate (Metabolite 2) has been detected in the urine and also in negligible amounts in the plasma. In healthy volunteers and in patients with type 2 diabetes, the steady-state concentration of Metabolite 1 is six to seven times that of troglitazone and Metabolite 3. In in vivo drug interaction studies, troglitazone has been shown to induce cytochrome P450 CYP3A4 at clinically relevant doses.
- Half life10 to 39 h.
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A